Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2006

View Archived Issues

Snapshots of histone deacetylases (HDACs) as novel effective targets in cancer therapy: Part II

New preclinical and clinical data presented on talampanel in seizures

TOP, PaTH studies reveal benefit of parathyroid hormone (1-84) in osteoporosis

PAR-101 effective against C. difficile-associated diarrhea

4SC and University of Munster collaborate on agents to target influenza

Serotonin necessary for liver regeneration

DPI and Infinity Pharmaceuticals sign definitive merger agreement

Characterization of novel dual targeting antibacterial agents from Vertex

Fast track designation for SinuNase in chronic sinusitis

Valeant to outlicense pradefovir

Series C financing at Novagali Pharma

Alnylam signs CRADA with U.S. Army on RNAi therapeutics for biodefense threats

Combination treatment studied for relapsing remitting MS

Glypromate completes phase II study in CABG patients

Japanese rimonabant rights to be transferred to sanofi-aventis

Evista offers no cardioprotection in RUTH study

Recent patents describe novel agents for cardiovascular disorders

Novel agents for hepatic disorders claimed in recent patents

Novel MRI contrast agent developed at Kyushu University

Vivitrol approved for treatment of alcohol dependence

Preclinical data presented on Aegera neuroprotectant for chemotherapy-induced neuropathy

Chugai files for Japanese approval of erlotinib in NSCLC

Vaccination with PN-277 may be useful in preventing retinal neurodegeneration

New antibacterial dianthraquinone derivatives identified

Novel antimicrobial agents demonstrate excellent in vitro activity against C. difficile

Thiazolidinedione derivative may be useful in chronic lymphocytic leukemia

A novel c-Met kinase inhibitor from Pfizer could be a potential anticancer therapy

Ecopia BioSciences presents preclinical data on its anticancer compound ECO-4601

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....